Please login to the form below

Not currently logged in
Email:
Password:

eye disease

This page shows the latest eye disease news and features for those working in and with pharma, biotech and healthcare.

UK firm Nightstar bags FDA fast-track status for gene therapy

UK firm Nightstar bags FDA fast-track status for gene therapy

A gene therapy for an inherited eye disease developed by Nightstar Therapeutics has picked up a coveted designation from the FDA that could accelerate its development. ... of the therapy into one eye and compared to a group with no treatment.

Latest news

  • Novartis buys gene therapy firm AveXis for $8.7bn Novartis buys gene therapy firm AveXis for $8.7bn

    ex-US rights to Spark Therapeutics’recently-approved Luxturna (voretigene neparvovec-rzyl) for an inherited eye disease. ... Last year, Biogen secured approval for the first drug treatment for SMA, a progressive, debilitating muscle-wasting disease

  • NICE backs GSK’s €594k gene therapy for rare disease NICE backs GSK’s €594k gene therapy for rare disease

    Children with the rare disease have compromised immune systems and are extremely vulnerable to infections, and usually are kept in isolation. ... The new guidance comes in the same week that Spark Therapeutics announced its pricing for RPE65-mediated eye

  • Shire files dry eye drug lifitegrast in Europe Shire files dry eye drug lifitegrast in Europe

    Shire is awaiting the go-ahead of lifitegrast in the EU, seeking approval for the would-be dry eye disease blockbuster. ... Dry eye disease causes discomfort, stinging and blurry vision, and can significantly affect quality of life in some patients,

  • European Commission approves Dompé’s orphan drug European Commission approves Dompé’s orphan drug

    Italian biopharmaceutical company Dompé has received the go-ahead for Oxervate (cenegermin) for the treatment of moderate-to-severe neurotrophic keratitis (NK), a rare eye disease that affects less than five ... The approval is a milestone for patients

  • Spark closes on first US gene therapy approval Spark closes on first US gene therapy approval

    Spark closes on first US gene therapy approval. FDA starts review of Luxturna for patients with inherited retinal disease. ... The FDA has started its review of Spark Therapeutics' rare eye disease treatment Luxturna which, if approved, will be the first

More from news
Approximately 6 fully matching, plus 47 partially matching documents found.

Latest Intelligence

  • Pharma deals during March 2013 Pharma deals during March 2013

    However, ophthalmology is increasingly an area of interest in the industry with potential for growth as the global population ages; it is estimated that around 25m people have dry eye disease ... 175. SARcode Bioscience/ Shire. Acquisition. SAR 1118 for

  • Interview: Joseph Jimenez, Novartis Interview: Joseph Jimenez, Novartis

    There is a growing demand for eye care, owing to the rising prevalence of eye disease, an ageing global population and increased demand for healthcare in emerging markets. ... This is demonstrated by the fact that rare disease research is central to its

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

  • The power of observation in gathering patient insights

    For example, we recently conducted a multi-country research project for a rare eye disease. ... Patients walked us around their homes; sharing with us stories about life before and after their disease, adding significant layers of insight to the findings

  • PAN trio run for charity

    RP is an inherited disease of the eye, where the light sensitive cells of the retina cease to function and die away. ... However, the research being undertaken at Moorfields Eye Hospital hopes to slow or even reverse this disease by injecting cells from

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Conversis

Conversis is a translation company specialising in translation and localisation for the Life Science and Pharmaceutical industry, with particular focus...

Latest intelligence

GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....
The rise of vertical integration in the US payer landscape
Is it a solution to addressing the challenges of the value-based marketplace?...

Infographics